Eli Lilly & Co. surged in early trading as its experimental Alzheimer’s drug showed promise in a mid-stage clinical trial, boosting hopes for progress against the debilitating, progressive brain disorder.
The drug, donanemab, slowed decline of a composite measure of patient cognition and function by 32% relative to placebo in patients with early Alzheimer’s, the Indianapolis-based company said Monday in a statement.
